ENDOSCOPY SUITE · COLONOSCOPY ACTIVE · TOPIC: INFLAMMATORY BOWEL DISEASE · REF: AGA / CCF / FDA

The Endoscopy Suite Gastroenterology reference · U.S. edition

Gastroenterology · Immune-mediated

Inflammatory bowel disease is not a stomach ache. It is a lifelong immune attack on the digestive tract.

Roughly 3 million American adults live with Crohn's disease or ulcerative colitis. Both conditions are chronic, immune-mediated, and increasingly manageable with modern therapies — but they require long-term monitoring, careful medication management, and a care team that understands the disease is more than its symptoms. This is the practical guide.

16 min read

AGA-aligned

5 tiers · 4 biologic targets

3M+

U.S. adults live with Crohn's disease or ulcerative colitis — about 1 in 100.

30–50%

Of patients develop at least one extraintestinal manifestation — joints, skin, eyes, or liver.

75%

Of Crohn's patients eventually require surgery — though modern biologics are reducing this.

2×

Colorectal cancer risk in extensive, long-standing colitis — regular surveillance matters.

Section 01 · The mechanism

When the immune system mistakes the gut for a threat.

Inflammatory bowel disease (IBD) is the umbrella term for two related conditions — Crohn's disease and ulcerative colitis — that share a common driver: an abnormally aggressive immune response against the tissues of the gastrointestinal tract. It is not caused by a food, an infection, or stress, and it is not the same as irritable bowel syndrome (IBS), which produces symptoms without visible inflammation or damage.

The mechanism involves three interacting factors. First, genetics — over 200 genetic variants have been associated with IBD, and first-degree relatives have an 8- to 10-fold increased risk. Second, the gut microbiome — patients with IBD have a less diverse and differently composed bacterial community, and the immune system reacts to it abnormally. Third, a triggering event — often an infection, a course of antibiotics, or an environmental exposure — that converts a predisposed immune system into an active, self-sustaining attack.

What follows is a chronic, relapsing-remitting inflammatory cascade that involves many of the same cytokines seen in psoriasis and rheumatoid arthritis. TNF-α, IL-12, IL-23, and the integrin α4β7 all play central roles. This is why many modern IBD drugs target the same pathways as dermatology and rheumatology drugs — and why the field of "immune-mediated inflammatory diseases" increasingly treats these conditions as variations on a shared theme.

What the immune attack actually does to the bowel wall differs by condition. In ulcerative colitis, inflammation is confined to the mucosa (the inner lining) and starts in the rectum, spreading upward continuously. In Crohn's disease, inflammation is transmural — it involves the full thickness of the bowel wall — and can affect any segment from mouth to anus, often with patches of healthy tissue in between. Transmural inflammation is why Crohn's produces fistulas, strictures, and abscesses at higher rates than UC.

Section 02 · Two diseases, one umbrella

Crohn's vs ulcerative colitis — the differences that shape treatment.

Crohn's disease — patchy, transmural

Any part of the GI tract

Location: anywhere from mouth to anus — most often the terminal ileum and colon.
Pattern: segmental — inflamed patches separated by normal, "skip" areas.
Depth: transmural (full thickness) — leads to strictures, fistulas, abscesses.
Symptoms: abdominal pain, diarrhea, weight loss, fatigue, perianal disease, obstruction.
Endoscopy: aphthous ulcers, cobblestoning, deep linear ulcers.
Surgery: common (up to 75% of patients) — but not curative, disease recurs.
Smoking: worsens the disease — cessation strongly recommended.

Ulcerative colitis — continuous, mucosal

Colon only

Location: colon only — always starts in the rectum and extends continuously upward.
Pattern: continuous — no skip lesions.
Depth: mucosal (inner lining only) — strictures and fistulas are rare.
Symptoms: bloody diarrhea, urgency, tenesmus, abdominal cramping.
Endoscopy: loss of vascular pattern, friability, erosions, pseudopolyps.
Surgery: colectomy is curative for the colon — but pouch or stoma decisions are significant.
Smoking: paradoxically protective in UC — but never a reason to smoke.

About 10 percent of cases are classified as IBD-unclassified (IBD-U). These are patients whose disease has features of both conditions — usually colitis that cannot yet be categorized as definitively Crohn's or UC. Many are re-classified over time as more clinical, endoscopic, and pathological information accumulates. The distinction matters for treatment selection and surgical planning, but does not change the underlying immune mechanism.

Section 03 · Classification

The Montreal classification — how IBD is described in clinical practice.

The Montreal classification describes IBD by age of onset, location, and behavior for Crohn's, and by extent and severity for UC. It provides a common language that guides treatment and prognosis.

Montreal classification · key categories

Crohn's disease and ulcerative colitis

Category	Code	Meaning
Crohn's age of onset	A1 / A2 / A3	A1 = below 16 (early onset); A2 = 17–40 (typical); A3 = above 40 (late onset). Early onset tends to be more aggressive.
Crohn's location	L1 / L2 / L3 / L4	L1 = ileal; L2 = colonic; L3 = ileocolonic; L4 = upper GI involvement. Add "p" for perianal disease.
Crohn's behavior	B1 / B2 / B3	B1 = inflammatory (non-structuring, non-penetrating); B2 = stricturing; B3 = penetrating (fistulizing). B2 and B3 usually require surgery or biologic escalation.
UC extent	E1 / E2 / E3	E1 = proctitis (rectum only); E2 = left-sided colitis (up to splenic flexure); E3 = pancolitis (entire colon). E3 carries the highest colorectal cancer risk.
UC severity (Mayo score)	0–12	Combines stool frequency, rectal bleeding, endoscopic findings, and physician assessment. Scores 0–2 = remission; 3–5 = mild; 6–10 = moderate; 11–12 = severe.

Section 04 · Treatment ladder

Five tiers — and the modern shift toward early biologic therapy.

Treatment approach depends on disease severity, location, behavior, and patient preference. What has changed in the last decade is that "step-up" therapy — starting with the mildest drug and escalating only if needed — is no longer automatic. For moderate-to-severe disease, many specialists now start with a biologic.

◆ IBD TREATMENT LADDER Individualize by severity and disease behavior

5-ASAs — mild UC, first-line

Mesalamine (5-aminosalicylic acid) formulations — oral, rectal, or both. Effective for mild-to-moderate ulcerative colitis, especially with topical treatment for proctitis or left-sided disease. Rarely sufficient for Crohn's, where they have limited evidence.

Well tolerated; occasional kidney or pancreatic effects require periodic monitoring. Given once daily with newer formulations.

Examplesmesalamine (Apriso, Lialda, Pentasa, Canasa, Rowasa) · sulfasalazine · balsalazide

Immunomodulators — steroid-sparing maintenance

Azathioprine, 6-mercaptopurine, and methotrexate are used as maintenance agents — to reduce steroid dependence and to keep disease quiet between biologics. Slow onset (8–12 weeks) but effective long-term. Often used in combination with a biologic — the "combination therapy" strategy in Crohn's has better outcomes than either agent alone.

Require blood monitoring for liver function, blood counts, and (for thiopurines) TPMT/NUDT15 genotyping. Methotrexate requires folic acid and pregnancy prevention. All increase infection risk and require monitoring.

Examplesazathioprine · 6-mercaptopurine · methotrexate

Anti-TNF biologics — the workhorses

Infliximab, adalimumab, and certolizumab have been the backbone of IBD therapy since the 2000s. Reduce hospitalizations, surgeries, and steroid use, and induce mucosal healing in 40–60 percent of patients. Biosimilars have made them more affordable in recent years.

Require baseline tuberculosis screening and monitoring for infections, infusion reactions, and (rarely) demyelinating events or lymphoma. Combining with an immunomodulator improves efficacy but increases infection risk.

Examplesinfliximab (Remicade, biosimilars) · adalimumab (Humira, biosimilars) · certolizumab pegol

Integrin inhibitors & IL-12/23 — gut-selective options

Vedolizumab (anti-α4β7 integrin) blocks lymphocyte migration into the gut specifically — less systemic immunosuppression, no known TB risk. Ustekinumab (anti-IL-12/23) targets a key cytokine shared with psoriasis. Both are well tolerated and preferred in some patient groups.

Risperidone-free approach to systemic immunosuppression — the reason these are favored in patients with prior infections or malignancy concerns. Response may be slower than anti-TNF.

Examplesvedolizumab (Entyvio) · ustekinumab (Stelara)

JAK inhibitors & next-generation IL-23 — latest approvals

Upadacitinib and tofacitinib are oral small molecules that block JAK-STAT signaling — rapid onset and oral administration, but carry boxed warnings for serious infections, thrombosis, and malignancy. Risankizumab, mirikizumab, and guselkumab target IL-23 specifically and have shown strong efficacy in Crohn's and UC.

The treatment landscape is evolving rapidly, and the correct agent depends on disease behavior, prior response, comorbidities, and patient priorities. The choice is best made with an IBD specialist.

Examplesupadacitinib (Rinvoq) · tofacitinib (Xeljanz) · filgotinib (not in U.S.) · risankizumab (Skyrizi) · mirikizumab (Omvoh) · guselkumab (Tremfya)

Section 05 · Biologic targets

Four pathways — and why the target matters.

TARGET · TNF-α

Tumor necrosis factor

A master inflammatory cytokine elevated in both Crohn's and UC. Blocking it reduces inflammation, promotes mucosal healing, and reduces surgeries. The most established class, with biosimilars making them more affordable.

Requires TB screening. Rare risks: demyelinating disease, lymphoma (especially in young males on combination therapy).

infliximab · adalimumab · certolizumab

TARGET · α4β7

Gut-homing integrin

Blocks the integrin that T lymphocytes use to enter the gut wall. Gut-selective — minimal systemic immunosuppression. No TB screening required. Preferred in patients with prior infection or malignancy history.

Slower onset than anti-TNF. Used in both UC and Crohn's. No cases of PML reported (unlike the older α4 inhibitor natalizumab).

vedolizumab

TARGET · IL-12/23

p40 subunit blockade

Blocks the shared p40 subunit of IL-12 and IL-23. Effective in Crohn's and UC. Well tolerated, no known TB risk, no boxed warning for malignancy. Given as a single IV loading dose, then subcutaneous injections every 8 weeks.

Also FDA-approved for psoriasis and psoriatic arthritis — useful in patients with both conditions.

ustekinumab

TARGET · IL-23

p19-specific inhibitors

The newest and most selective class — blocks only IL-23 (not IL-12). High rates of endoscopic remission in recent trials in both UC and Crohn's. Rapidly becoming a preferred first biologic in some centers.

Given as IV induction followed by subcutaneous maintenance every 4 to 8 weeks.

risankizumab · mirikizumab · guselkumab

Section 06 · Safety monitoring

What to monitor on IBD therapy — and what to tell every prescriber.

IBD medications require structured monitoring. The specific tests depend on the drug class, but the principles are consistent: screen before starting, monitor during treatment, and know the warning signs that require urgent evaluation.

MONITORING · EVERY DRUG CLASS

Before starting any biologic or immunomodulator, these baselines are essential.

Tuberculosis screening

Required before any anti-TNF agent and JAK inhibitor. Latent TB must be treated before starting therapy. Skin test or IGRA blood test plus chest X-ray if positive.

Hepatitis B & C serologies

Hepatitis B can reactivate on immunosuppression. Screen and vaccinate or treat before starting, especially before anti-TNF or JAK inhibitors.

Blood counts & liver panel

Baseline CBC, CMP, and specific labs for the drug class. Thiopurines require TPMT/NUDT15 genotyping to avoid severe myelosuppression.

Vaccinations up to date

Live vaccines are contraindicated on most biologics. Bring all non-live vaccines up to date before starting — flu, COVID, pneumococcal, shingles, hepatitis B.

Complete medication list

Interactions matter. Give every prescriber and pharmacist a complete list — including over-the-counter drugs and supplements. A live resource that demonstrates this is Metformin interactions, showing how routine interaction screening catches things patients often miss.

Cancer surveillance

Long-standing colitis increases colorectal cancer risk. Surveillance colonoscopy begins 8 years after diagnosis and continues every 1–3 years depending on risk.

Section 07 · Beyond the gut

Extraintestinal manifestations — IBD is not confined to the bowel.

Between 30 and 50 percent of IBD patients develop inflammation outside the gastrointestinal tract. These are not complications of the disease — they are the same immune process showing up in other tissues, and they often require coordinated care.

Joints — peripheral & axial

Peripheral arthritis affects large joints (knees, ankles, wrists) and tracks disease activity. Axial arthritis affects the spine and sacroiliac joints and does not track bowel disease activity. Up to 30% of IBD patients have some form of joint involvement.

Skin — pyoderma & erythema nodosum

Erythema nodosum produces tender red nodules on the shins; pyoderma gangrenosum produces painful ulcers. Both are more common in UC. Treating the underlying IBD is the priority. Dermatology co-management helps.

Eyes — uveitis & episcleritis

Uveitis is painful and can threaten vision if untreated; episcleritis is usually mild and self-limited. Any eye redness or pain in a patient with IBD warrants an ophthalmology evaluation.

Metabolic & other conditions

Patients with IBD have elevated rates of fatty liver disease, osteoporosis, kidney stones, and anemia. Chronic steroid use contributes to several of these. Managing multiple conditions often means managing multiple prescribers — a clear diabetes management guide approach to coordinating care is a useful template.

Section 08 · What to watch for

Signs that require urgent medical evaluation.

Urgent evaluation

If any of these appear, contact the care team right away or go to the emergency department.

Severe abdominal pain with fever, rigid abdomen, or new distension. Could indicate toxic megacolon, perforation, or intra-abdominal abscess — surgical emergencies.

Heavy rectal bleeding or blood in stools with dizziness or fainting. Requires immediate evaluation for severe bleeding.

Persistent vomiting, inability to keep anything down, or signs of dehydration. Particularly concerning in Crohn's with strictures — could indicate obstruction.

Fever during biologic therapy. Immunosuppression can mask or worsen infections. Do not wait — contact the treating clinician the same day.

New severe headache, vision changes, or neurological symptoms on any biologic. Rarely, biologic therapy is associated with demyelinating or neurologic events. Requires prompt evaluation.

Sudden pain or swelling in one leg, chest pain, or shortness of breath. JAK inhibitors carry a boxed warning for thrombosis. These symptoms require emergency evaluation.

Section 09 · Access & affordability

IBD biologics are expensive. Copay assistance helps most patients.

5-ASAs and immunomodulators are generic and inexpensive — mesalamine brand names are costly but generic formulations exist, and azathioprine/methotrexate cost a few dollars per month. Anti-TNF biosimilars have substantially reduced the cost of that class in the U.S. over the past few years. Newer agents — ustekinumab, vedolizumab, risankizumab, upadacitinib — remain brand-only and expensive, typically $60,000 to $120,000 per year without insurance.

Manufacturer copay assistance programs cover most of the out-of-pocket cost for commercially insured patients, often reducing the cost to $0–$5 per fill. Patients on Medicare or Medicaid cannot legally receive manufacturer copay assistance, but grants from independent foundations like the HealthWell Foundation or the PAN Foundation typically cover the same costs. Every specialty pharmacy and every IBD center has staff whose job is to help with these programs — ask them directly. Some patients find it useful to see how pharmacy-level pricing varies for other chronic medications, for example the range shown for affordable Metformin online, because the same pricing dynamics apply to many IBD drugs at the generic level.

What still varies at the pharmacy counter for generics: the same tablet can cost several times more at one licensed pharmacy than another. If you are filling an online refill for the first time, the process is documented step by step in this order Metformin online guide — prescription first, licensed seller second, small first order third. Most IBD biologics must be dispensed through specialty pharmacies and administered under medical supervision, so this applies mainly to oral medications.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.

Section 10 · Questions

Five asked most often at the IBD clinic.

Q·01 What is the difference between Crohn's disease and ulcerative colitis? +

Both are chronic inflammatory bowel diseases, but they differ in location and pattern. Ulcerative colitis involves only the colon, starting in the rectum and extending continuously upward. Crohn's disease can affect any part of the gastrointestinal tract from mouth to anus, often in patchy segments with healthy tissue between them, and can involve the full thickness of the bowel wall. About 10 percent of cases are classified as IBD-unclassified when features overlap.

Q·02 Are biologics safe for IBD? +

Biologics are generally well tolerated and have transformed IBD outcomes, but they require monitoring. The main concerns are infection risk — particularly tuberculosis reactivation, which is screened for before starting — and, for some classes, a small increased risk of certain malignancies and neurologic conditions. Regular follow-up with a gastroenterologist and periodic lab monitoring are essential.

Q·03 What is 'treat to target' in IBD? +

Treat to target is a modern strategy in which therapy is adjusted to achieve objective endpoints — resolution of inflammation on endoscopy or imaging, normalization of inflammatory markers, and symptom control — rather than just symptom relief. Studies show that patients managed this way have fewer hospitalizations, surgeries, and long-term complications than those managed on symptoms alone.

Q·04 Do IBD medications interact with other prescriptions? +

Yes, and the interactions are clinically important. Methotrexate interacts with many drugs and requires folic acid supplementation. Azathioprine and 6-mercaptopurine interact with allopurinol and require dose adjustment. Biologics have fewer direct drug interactions but can compound immunosuppression when combined. Always give every prescriber and pharmacist a complete list of everything you take.

Q·05 Can diet cure IBD? +

No. No diet has been shown to cure or fully control IBD, and claims to the contrary should be treated with skepticism. Certain diets — exclusive enteral nutrition in children, the specific carbohydrate diet, and the Mediterranean pattern — may help manage symptoms or support mucosal healing in some patients, but they do not replace medication. A registered dietitian familiar with IBD is a valuable partner.

◆ Sources & Verification

This reference is aligned with public clinical guidance from the American Gastroenterological Association (AGA), the Crohn's & Colitis Foundation, the National Institute of Diabetes and Digestive and Kidney Diseases (NIH), and the U.S. Food and Drug Administration's BeSafeRx program. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.

◆ Before the next refill

IBD is manageable. Prescription pricing should not be the obstacle.

Many IBD medications are available as low-cost generics, and the same tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Start with the current affordable Metformin online comparison as a live demonstration of how wide the spread runs — the same pricing dynamics apply to every generic on a patient's list.

Open the price comparison